Regulatory & Reimbursement
FDA Output July 2021
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in July 2021. Updated July 31, 2021.
Welcome to MyStrategist, the digital home for Market Pathways.
Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically.
Subscribe Today
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Regulatory & Reimbursement
FDA Output July 2021
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in July 2021. Updated July 31, 2021.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
CMS Ponders the Path Ahead for AI Payments
The Medicare agency acknowledges its methodologies to calculate payments are not well-suited to account for the costs and efficiencies of AI software. In its 2022 Physician Fee Schedule proposal out this week, CMS is seeking detailed input to help reform its systems while trying to come up with temporary solutions to provide sufficient reimbursement in the short term.